Question 1

What is Vertex Pharmaceuticals's P/S ratio?

Accepted Answer

Vertex Pharmaceuticals (VRTX) P/S ratio is 9.9× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month revenue, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/S ratio calculated?

Accepted Answer

P/S = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Revenue, or equivalently Share Price ÷ TTM Revenue Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/S ratio?

Accepted Answer

The price-to-sales (P/S) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) revenue. It is calculated as market cap ÷ TTM revenue (equivalent to share price ÷ TTM revenue per share). Because the denominator (revenue) cannot be negative, P/S is widely used to value unprofitable or pre-profit companies and to make cross-sector comparisons.

Question 4

What is a good P/S ratio for Vertex Pharmaceuticals?

Accepted Answer

A "good" P/S depends heavily on profit margin and growth: software and other high-margin businesses often command 5–15× sales, while low-margin retailers and commodity producers typically trade below 1×. Compare against sector peers rather than absolute thresholds. For Vertex Pharmaceuticals specifically, the relevant sector benchmark is the current sector median of 3.4×.

Question 5

Is Vertex Pharmaceuticals's P/S ratio high or low?

Accepted Answer

Vertex Pharmaceuticals's P/S ratio of 9.9× is above its own 5-year average of 9.3× and above the sector median of 3.4×. That places the current reading at the 58th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Vertex Pharmaceuticals's historical P/S ratio range?

Accepted Answer

In the available daily series, Vertex Pharmaceuticals (VRTX) P/S ratio has ranged from a low of 4.8× in 2012 to a high of 83.7× in 2009. The 5-year average is 9.3× and the 5-year median is 9.3×.

Question 7

What was Vertex Pharmaceuticals's P/S ratio in 2025?

Accepted Answer

Vertex Pharmaceuticals (VRTX) P/S ratio at the end of 2025 was 9.6×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month revenue figure available at that date.

Question 8

Why does Vertex Pharmaceuticals's P/S ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (revenue). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$115B	$12B	9.6×	+0.1×	Dec 31, 2025
2024	$104B	$11B	9.4×	-1.2×	Dec 31, 2024
2023	$105B	$9.87B	10.6×	+2.3×	Dec 31, 2023
2022	$74.2B	$8.93B	8.3×	+0.9×	Dec 31, 2022
2021	$55.9B	$7.57B	7.4×	-2.5×	Dec 31, 2021
2020	$61.5B	$6.21B	9.9×	-3.7×	Dec 31, 2020
2019	$56.5B	$4.16B	13.6×	-0.3×	Dec 31, 2019
2018	$42.2B	$3.05B	13.9×	-1.3×	Dec 31, 2018
2017	$37.7B	$2.49B	15.1×	+4.5×	Dec 31, 2017
2016	$18.1B	$1.7B	10.6×	-18.6×	Dec 31, 2016
2015	$30.1B	$1.03B	29.2×	-19.5×	Dec 31, 2015
2014	$28.3B	$580M	48.7×	+34.5×	Dec 31, 2014
2013	$17.2B	$1.21B	14.2×	+8.3×	Dec 31, 2013
2012	$8.99B	$1.53B	5.9×	+1.0×	Dec 31, 2012
2011	$6.91B	$1.41B	4.9×	-44.3×	Dec 31, 2011
2010	$7.05B	$143M	49.2×	-34.5×	Dec 31, 2010
2009	$8.52B	$102M	83.7×	+57.9×	Dec 31, 2009
2008	$4.52B	$176M	25.8×	+10.5×	Dec 31, 2008
2007	$3.04B	$199M	15.3×	-6.2×	Dec 31, 2007
2006	$4.64B	$216M	21.5×	+3.0×	Dec 31, 2006
2005	$2.97B	$161M	18.5×	+10.3×	Dec 31, 2005
2004	$836M	$103M	8.1×	-3.5×	Dec 31, 2004
2003	$805M	$69.1M	11.6×	+4.1×	Dec 31, 2003
2002	$1.21B	$161M	7.5×	—	Dec 31, 2002


Zimmer Biomet Holdings (ZBH)	2.1×
AptarGroup (ATR)	2.1×
Becton, Dickinson and (BDX)	2.1×
Charles River (CRL)	1.9×
Quest Diagnostics (DGX)	1.9×
IQVIA (IQV)	1.7×
GE HealthCare (GEHC)	1.6×
Labcorp Holdings (LH)	1.6×
HCA Healthcare (HCA)	1.4×
Solventum (SOLV)	1.4×
Viatris (VTRS)	1.1×
UnitedHealth Group (UNH)	0.8×
Baxter International (BAX)	0.8×
DaVita (DVA)	0.7×
Henry Schein (HSIC)	0.6×
Universal Health Services (UHS)	0.6×
Elevance Health (ELV)	0.4×
Teladoc Health (TDOC)	0.4×
McKesson (MCK)	0.3×
Cigna (CI)	0.3×
CVS Health (CVS)	0.2×
Cardinal Health (CAH)	0.2×
Cencora (COR)	0.2×
Humana (HUM)	0.2×
Centene (CNC)	0.1×

P/S Ratio for Vertex Pharmaceuticals (VRTX) 2002-2026

P/S Ratio daily chart for Vertex Pharmaceuticals (VRTX)

Historical P/S Ratio for Vertex Pharmaceuticals (VRTX) from 2002 to 2025

About P/S Ratio at Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals P/S Ratio by Year

Vertex Pharmaceuticals P/S Ratio 2025: 9.6×

Vertex Pharmaceuticals P/S Ratio 2024: 9.4×

Vertex Pharmaceuticals P/S Ratio 2023: 10.6×

Vertex Pharmaceuticals P/S Ratio 2022: 8.3×

Vertex Pharmaceuticals P/S Ratio 2021: 7.4×

Sector peers by P/S Ratio — chart

Sector peers by P/S Ratio — table

Frequently asked questions

Vertex Pharmaceuticals (VRTX) Key Financials